Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 21, Issue 12, Pages 1473-1480
Publisher
Springer Nature
Online
2015-11-17
DOI
10.1038/nm.3995
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation
- (2015) B. Goldenson et al. BLOOD
- Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells
- (2014) Meng Zhao et al. NATURE MEDICINE
- Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion
- (2014) Ingmar Bruns et al. NATURE MEDICINE
- The aurora kinases in cell cycle and leukemia
- (2014) B Goldenson et al. ONCOGENE
- A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
- (2013) J. Mascarenhas et al. BLOOD
- Myeloproliferative Neoplasia Remodels the Endosteal Bone Marrow Niche into a Self-Reinforcing Leukemic Niche
- (2013) Koen Schepers et al. Cell Stem Cell
- Investigational Janus kinase inhibitors
- (2013) Constantine S Tam et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Kinetic Test Characterizes Kinase Intramolecular and Intermolecular Autophosphorylation Mechanisms
- (2013) C. A. Dodson et al. Science Signaling
- Practical management of patients with myelofibrosis receiving ruxolitinib
- (2013) Claire Harrison et al. Expert Review of Hematology
- Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium
- (2012) Omar Abdel-Wahab et al. AMERICAN JOURNAL OF HEMATOLOGY
- JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
- (2012) A. Tefferi BLOOD
- Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL
- (2012) Qiang Wen et al. CELL
- Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms
- (2012) Raoul Tibes et al. Molecular Diagnosis & Therapy
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms
- (2011) Gregor Hoermann et al. FASEB JOURNAL
- Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells
- (2011) Kazuya Sumi et al. FEBS LETTERS
- Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
- (2010) P. Koppikar et al. BLOOD
- Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state
- (2010) J. den Hollander et al. BLOOD
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines
- (2008) Oliver Bock et al. AMERICAN JOURNAL OF PATHOLOGY
- The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
- (2008) G. Wernig et al. BLOOD
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
- Aurora-A Kinase Is Essential for Bipolar Spindle Formation and Early Development
- (2008) D. O. Cowley et al. MOLECULAR AND CELLULAR BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started